NASDAQ
1.81USD
-0.04 (-2.16%)
We have scored 16 news catalysts on Scilex Holding Company (SCLX) over the past 12 months. The biggest single-day move next to one of them came Nov 21, 2025, when SCLX closed +18.8%: “Datavault AI Just Raised Guidance by 400%—Are You Paying Attention?”. Coverage across the window leans mixed (average ticker sentiment −0.05). Most of the impact sits in institutional appeal and price momentum.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
12.7M
P/E
—
EPS
—
Beta
1.83
52W range
1.81-27
Day range
1.81–1.89
Open
1.89
Prev close
1.85
Volume
32.2K
Avg volume
104.5K
Dividend
0.00
IPO
2021-03-05
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Scilex Holding Company — not a sector bucket. Click an edge to see the articles that established the link.
Suppliers, customers, partners and competitors of Scilex Holding Company, taken from what the news actually said about them rather than from a sector bucket. The count is how many articles established each link.
Latest scored catalyst for SCLX: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Scilex Holding Company is a biopharmaceutical enterprise that specializes in the development and market introduction of non-opioid therapies designed to alleviate both acute and chronic pain. Its primary marketed offering is ZTlido 1.8%, a topical prescription formulation of lidocaine specifically engineered to mitigate neuropathic discomfort associated with post-herpetic neuralgia, a condition characterized by persistent nerve pain following shingles. Beyond this, the company's development pipeline includes SP-102, a viscous gel corticosteroid for epidural administration, currently undergoing Phase III trials for lumbosacral radicular pain. Another candidate, SP-103, is progressing through Phase II trials for managing low back pain. Furthermore, SP-104, a novel, low-dose, delayed-release naltrexone hydrochloride formulation, has successfully concluded Phase I clinical testing for the treatment of fibromyalgia. Its corporate offices are situated in Palo Alto, California. Scilex Holding Company operates as a subsidiary of Sorrento Therapeutics, Inc.
